Author:
Kattakuzhy Sarah,Levy Rachel,Kottilil Shyam
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2013;56:3359–3368
2. Klein R, Struble K. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. Federal Drug Administration 2013, Published 6 Dec 2013. http://www.fda.gov/ForPatients/Illness/HepatitisBC/ucm377920.htm
3. Sofia MJ, Bao D, Chang W, et al. Discovery of a β-d-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53(19):7202–7218
4. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337–34347
5. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype-1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58(4):663–668
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献